By contrast, when IRE and anti-CTLA-4 primary therapy was followed up by secondary therapy with anti-PD-1, the average tumor growth was held in check resulting in tumor sizes significantly smaller than the endpoint values of sham-treated tumors (Fig. 9d). The gene discussed is CTLA4; the disease is neoplasm.